Clinical trial · Observational
SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access
NCT02214134CI-TRIAL-00093775SPECTAlungcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
SPECTAlung is a program aiming at screening patients with thoracic tumors to identify the molecular characteristics of their disease. The thoracic tumors include lung cancer, malignant pleural mesothelioma, thymoma or thymic carcinoma at any stage. Once the molecular characteristics are identified, there might be the possibility to offer these patients access to targeted clinical trials.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Any Stage of Any Thymic Malignancy | — | UNRESOLVED | — |
| Any Stage of Lung Cancer (Any Histotype) | — | UNRESOLVED | — |
| Any Stage of Malignant Pleural Mesothelioma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tumour markers testing | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Lung cancer
- description
- Patients with diagnosis of lung cancer at any stage
- interventionNames
- Genetic: Tumour markers testing
- label
- Malignant pleural mesothelioma
- description
- Patients with diagnosis of malignant pleural mesothelioma at any stage
- interventionNames
- Genetic: Tumour markers testing
- label
- Thymic malignancy
- description
- Patients with diagnosis of thymic malignancy at any stage
- interventionNames
- Genetic: Tumour markers testing
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed lung cancer, MPM, thymoma or thymic carcinoma at any stage; * Mandatory availability of adequate Human Biological Material (HBM): FFPE tissue sample from the primary tumor, recurrent tumor, metastasis, obtained at the time of primary surgery or biopsy; minimal amount requested is detailed in the HBM guidelines; inclusion of samples taken at any recurrence diagnosed during follow-up is strongly encouraged but optional; * Centrally performed confirmation of tumor tissue adequacy in terms of quality/ quantity for central screening; * Age ≥ 18 years; * At least three months life-expectancy; * Written informed consent according to ICH/GCP and national/local regulations. Exclusion Criteria: * Any active malignancy, except pT1-2 prostatic cancer Gleason score \< 6, non melanomatous skin cancer or carcinoma in situ of the cervix, in the 5 years before study entry; * Active hepatitis B/C or HIV; * Any secondary malignancy; * Any severe organ dysfunction or other comorbidities that may prevent the inclusion into clinical trials.
References
Publications (0)
Data not yet available
No reference posted for this study.